Tranzactioneaza Biogen Inc (US.BIIB) - 187.65 USD (%) Tranzactioneaza
Stiri
Eli Lilly alzheimers eli lilly treatment solanezumab failed to slow disease 2023 ieri ca abandoneaza testarea unui tratament potential contra stagiilor incipiente ale bolii Alzheimer, denumit solanezumab. Totusi, compania va continua sa dezvolte alte doua tratamente, denumite donanemab si remternetug, care sunt in faze avansate de testare clinica.
In ianuarie, U.S. Food and Drug Administration (FDA) news release details sa avizeze donanemab, justificand ca are nevoie de date suplimentare. Decizia intarzie cu cel putin cateva luni lansarea comerciala a medicamentului, insa pe termen scurt articles un impact financiar substantial pentru companie, intrucat Medicare articles deocamdata sa acopere preturile noilor tratamente contra bolii Alzheimer.
In schimb, tot in ianuarie, FDA alzheimers disease fda decision on biogen eisai treatment lecanemab 2023 un aviz accelerat unui medicament similar, lecanemab, dezvoltat de Biogen in colaborare cu compania nipona Eisai. Cu un pret de 26,500 USD in SUA, medicamentul este disponibil din ianuarie, sub denumirea comerciala de Leqembi.
Gigantul farmaceutic elvetian Roche medtech, la randul sau, un tratament similar contra bolii Alzheimer.
(US.LLY) (US.BIIB) (DE.RHO6)
U.S. Food and Drug Administration (FDA) news release details sa avizeze medicamentul propus de Eli Lilly contra bolii Alzheimer, denumit donanemab, indicand ca are nevoie de date suplimentare din teste clinice.
Decizia va intarzia cu cel putin cateva luni lansarea comerciala a noului medicament. Potrivit unei estimari FactSet articles de WSJ la inceputul acestui an, vanzarile generate de donanemab sunt estimate la 1.05 mld. USD in 2024 si 2.1 mld. USD in 2027.
Pe termen scurt, insa, decizia FDA articles sa aiba un impact financiar substantial pentru Eli Lilly, intrucat Medicare articles deocamdata sa acopere preturile noilor medicamente destinate bolii Alzheimer. Eli Lilly va publica rezultatele financiare trimestriale pe 2 februarie.
In schimb, pe 6 ianuarie, FDA alzheimers disease fda decision on biogen eisai treatment lecanemab 2023 un aviz accelerat unui medicament similar, lecanemab, dezvoltat de Biogen in colaborare cu compania nipona Eisai. Cu un pret most alzheimers patients would pay up to 26500 per year for leqembi 2023 de 26,500 USD in SUA, medicamentul va fi comercializat din 23 ianuarie, sub denumirea de Leqembi. Potrivit aceleiasi estimari FactSet mentionate mai sus, vanzarile articles previzionate la 351 mil. USD in 2024 si 2.2 mld. USD in 2027.
Roche medtech un medicament similar, testele clinice fiind, si in acest caz, pe radarul FDA.
(US.LLY) (US.BIIB) (DE.RHO6)
U.S. Food and Drug Administration (FDA) alzheimers disease fda decision on biogen eisai treatment lecanemab 2023 vineri un aviz accelerat unui nou tratament destinat bolii Alzheimer, dezvoltat de Biogen impreuna cu compania nipona Eisai.
Este al doilea tratament contra bolii Alzheimer introdus in ultimii aproape 2 ani pentru care cele doua companii reusesc sa primeasca un aviz timpuriu din partea agentiei de reglementare americane. Pentru tratamentul avizat vineri, Eisai enews 02pdf 2023 un pret anual de 26,500 USD in SUA, unde va fi comercializat incepand din 23 ianuarie sub denumirea de Leqembi.
Eli Lilly 546289  avizul din partea FDA pentru un tratament similar, care articles genera incasari de 1.05 mld. USD in 2024 si de 2.1 mld. USD in 2027. Dezvoltat de Biogen si Eisai, Leqembi articles genera incasari de 351 mil. USD in 2024 si de 2.2 mld. USD in 2027. Roche medtech, la randul sau, un tratament asemanator.
Peste 6.5 milioane de americani cu varste care trec de 65 de ani  alzheimers disease facts figures#:~:text=More%20than%206,16%20million de boala Alzheimer, acest numar putand atinge 16 milioane pana in 2050.
In lume, peste 50 de milioane de oameni alzheimers disease facts figures#:~:text=Worldwide%2C%20at%20least% %20million%20people%20are%20believed%20to%20be%20living%20with%20Alzheimer%27s%20disease%20or%20other%20dementias %C2%A0According%20to%20the%20United%20Nations%2C%20that%20is%20more%20than%20the%20population%20of%20Colombia.5%C2%A0If%20breakthroughs%20are%20not%20discovered%2C%20rates%20could%20exceed%20152%20million%20by%20 2050 afectati de boala Alzheimer. In absenta unui tratament revolutionar, cifra ar putea depasi 152 de milioane pana in 2050.
(US.BIIB) (US.LLY)  (DE.RHO6)
An experimental Alzheimer's drug made by Eisai Co and Biogen (US.BIIB) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs. Multiple drugmakers have so far tried and failed to find an effective treatment for the brain-wasting disease that affects about 55 million people globally. A breakthrough would be a major boost to similar studies being run by Roche and Eli Lilly. 
The race to stem the progression of Alzheimer's comes as the number of Americans living with the disease is expected to roughly double to 13 million by 2050, according to the Alzheimer's Association. Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said.
eisai says alzheimers drug succeeds slowing cognitive decline 09 272022
Biogen, which won a controversial approval for its Alzheimer's treatment known as Aduhelm from the Food & Drug Administration last year, said adjusted earnings for the three months ending in March were pegged at $3.62 per share, down 32.2% improvement from last year but well shy of the Street consensus forecast of $4.38 per share. 
Biogen said the miss was linked in part to a 76 cents per share write-off of Aduhelm inventories. Group revenues, Biogen said, fell 6% from last year to $2.532 billion, a figure that topped analysts' estimates of a $2.5 billion tally. Biogen slashed the price of Aduhelm by around 50% in January, to $28,200 per year, in order to help expand its potential reach.
Medicare will deny routine payment for Biogen Inc.âs Alzheimerâs disease drug Aduhelm, finalizing an unusually strict policy that will require patients to enroll in clinical trials so the government will pay for the drug. The Medicare policy, which government officials announced on Thursday, is expected to significantly constrict the number of patients taking Aduhelm, as well as its commercial potential.
Biogen stock fell as management disclosed sales of its controversial Alzheimerâs disease therapy that once again fell short of what Wall Street had penciled in, and issued weaker-than-expected financial forecasts for 2022. Biogen has been facing a crisis since the Centers for Medicare and Medicaid Services last month issued a draft decision saying that Medicare wouldnât pay for Aduhelm except in the context of a clinical trial. Shares had fallen 15.9% over the past 12 months as of the close of trading on Wednesday.